Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 15Unknown 7Recruiting 5Active not recruiting 5Terminated 3Withdrawn 2Approved for marketing 2Not yet recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1

Interventions

Oxaliplatin 4Paclitaxel 3Capecitabine 3pembrolizumab 2fludarabine 2Trastuzumab 2S 1 (combination) 2Ramucirumab 2Polymerase Chain Reaction 2Irinotecan 2Gastric Bypass 2Fluorouracil 2Cyclophosphamide 2Biopsy 2zimberelimab 1tusamitamab ravtansine 1talazoparib 1relatlimab 1olaparib 1milademetan 1atezolizumab 1apatinib 1XELOX 1Valganciclovir 1Taxes 1Saline Solution 1Nivolumab 1Methods 1Lubricant Eye Drops 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Stomach Neoplasms × Ramucirumab × Clear all
NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Bristol-Myers Squibb

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

NCT03766607 2019-09-19

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Korean South West Oncology Group

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡